Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

GemPharmatech is a high-tech biotechnology enterprise specializing in the research and development of humanized models and drug screening technologies. It has a leading disease model research and development ability and a genetic engineering mouse model creation center.In 2018, the company's "Humanization Model and Drug Screening Innovation Technology Research Institute" was absorbed by the Jiangsu Industrial Technology Research Institute as a "professional research institute", and became a new research and development institution that supports the establishment of an industrial chain and international development in this field. The company aims to provide global partners with one-stop innovative technologies and resource services such as model creation, breeding, mouse sales, phenotypic analysis, and functional efficacy.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.

Part of Kontafarma China Holdings Ltd., SPF (Beijing) biotechnology Co. Ltd. is a company headquartered in zhongguancun, China, that engages in research and development of biomedical technology. It was founded in 2010.

Biositu Jiangsu Gene Biotechnology Co., Ltd., established on 2014-10-14, Business scope includes licensed projects:Offshore trade operation;Experimental animal production;Experimental animal management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology promotion and application services;Medical Research and Experimental Development;Technology Import and Export;Import and export agency;rental service(Licensed rental services not included);Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Saiye (Suzhou) Biotechnology Co., Ltd, established on 2011-05-27, Business scope includes bioengineering technology development,technical consulting,technology transfer,Technical Services,Research and development of biomedical materials and products;Distribution of experimental equipment;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Henan Provincial Peoples Hospital is a Chinese private company located in Zhengzhou. The firm operates as an hospital.

Chengdu Yaokang Biotechnology Co., Ltd., established on 2018-08-24, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Natural science research and experimental development;Animal Husbandry and Fishery Feed Sales;Laboratory Animal Bedding Sales;Disinfectant sales(Free of Hazardous Chemicals);internet sales(Except for products that require a license for sale);Information Consulting Service(Not including licensing information consulting services);Engineering Management Services;business management;Educational Consulting Services(Education and training activities that do not include licensing approval);Health Consulting Services(Does not include medical services);Conference and Exhibition Services;rental service(Licensed rental services not included);Import and export;Technology Import and Export;Import and export agency.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Experimental animal production;Experimental animal management;Inspection and testing service;road freight transport(Does not contain dangerous goods).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Toneker provides products and services in the field of life medicine. They also provide molecular diagnosis and gene detection technology services. Additionally, they also offer research and development, production and sales of clinical molecular testing reagents, and instruments.

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Shanghai Longsheng Biotechnology Co., Ltd., established on 2020-01-17, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;R&D and application of cell technology;Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Technology Import and Export;Import and export;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Chemical product sales(No licensed chemical products);Cosmetics Retail;Information Consulting Service(Not including licensing information consulting services);software development;data processing services;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Conference and Exhibition Services;Health Consulting Services(Does not include medical services).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:pharmaceutical production;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Nanmo Bio is a life sciences firm with a focus on genetically modified model organisms, mainly for life science gene function and drugs R&D.

Nanjing Meixinuo Pharmaceutical Technology Co., Ltd., established on 2008-06-02, The business scope includes anti-infective drugs,anticancer drug,endocrine system drugs,Geriatric Drugs,Research and development of drugs for cardiovascular system;Medical Technology Information Consulting,drug,pesticide,In vivo and in vitro metabolism analysis of veterinary drugs;Toxicogen Analysis and Organic Analysis Services;Import, export and wholesale business of detection and analysis instruments and their consumables(Commodities that do not involve state trade management,Quota involved,of license-managed goods,Apply in accordance with relevant national regulations)and provide related services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shenzhen Boao Kang Biotechnology Co., Ltd., established on 2013-11-04, Business scope includes general business items:Research on Biotechnology Products,Biological product,biotechnology products,Development of biochemical scientific research reagents and related technical services,Biochemical Research Instruments,Reagent,Sales of laboratory consumables;Operating Class II medical devices;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:

Guangdong Nanmo Biotechnology Co., Ltd., established on 2020-08-13, Business scope includes research and development:Biotechnology,Instrumentation;Technical extension services;Sales:Biological product,Instrumentation,laboratory equipment,Specialty Chemicals(Free of Hazardous Chemicals);Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(The above business scope involves the import and export of goods,Technology Import and Export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Fuda Cancer Hospital is a tertiary specialized cancer hospital which is affiliated with the Health Department of Guangdong Province in China. It was designated a national key clinical (cancer) hospital by the National Health and Family Planning Commission in 2011. The same year, Guangzhou Fuda Cancer Hospital was honored with National Trustworthy Private Hospital by the National Institute of Hospital Administration. In 2012, China Hospital Association rated Guangzhou Fuda Cancer Hospital as China Public Confidence Model Hospital. It was accredited by JCI in 2014.